Pazopanib for the treatment of soft-tissue sarcoma

Pazopanib for the treatment of soft-tissue sarcoma

Blog Article

Pierre Heudel,1 BEDS Philippe Cassier,1 Olfa Derbel,1 Armelle Dufresne,1 Pierre Meeus,2 Philippe Thiesse,3 Dominique Ranchère-Vince,4 Jean Yves Blay,1 Isabelle Ray-Coquard1,51Department of Medical Oncology, 2Department of Surgical Oncology, 3Department of Radiology, 4Department of Pathology, Leon Berard Center, Lyon, 5EAM 4128 Sante-Individu-Societe, Lyon University, Lyon, FranceAbstract: Pazopanib is a multikinase inhibitor which potently inhibits the activity of major receptor tyrosine kinases, including vascular endothelial growth factor receptor-1, vascular endothelial growth factor receptor-2, vascular endothelial growth factor receptor-3, platelet-derived growth factor receptor-a, platelet-derived growth factor receptor-a, and c-Kit.Approved by the Food and Drug Administration in Visors 2009 in the United States for the treatment of metastatic renal cell carcinoma, pazopanib has been tested in advanced or metastatic soft-tissue sarcoma.Unlike other tyrosine kinase inhibitors, a statistically significant efficacy in phase II but also in randomized phase III studies has been shown.In comparison with sunitinib or sorafenib, pazopanib has a similar toxicity profile and is generally well tolerated.This review details the development of this new therapeutic class in the treatment of metastatic soft-tissue sarcomas.

Keywords: soft-tissue sarcoma, pazopanib, tyrosine kinase inhibitor.